Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia

Dillman, R O; Shawler, DL; Sobol, RE; Collins, HA; Beauregard, JC; Wormsley, Susan B.; Royston, I

doi:10.1182/blood.v59.5.1036.bloodjournal5951036

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This has been observed in patients treated doubling time of 18 hr in vitro (de Both et al, 1981) on day 5 , with xenogeneic mouse MAbs, leading to reduction of therayields a maximum of 9.7 x lo8 RMB-1 cells. This would peutic efficacy (Miller et al, 1983) or to hypersensitivity imply that cures can be achieved in animals containing a reactions (Dillman et al, 1982). The use of syngeneic MAbs number of tumor cells that is approx.…”

Section: Discussionmentioning

confidence: 99%

Use of syngeneic monoclonal antibodies in the therapy of disseminated myeloid leukemic cells

Berends

Mulder

Houwelingen

et al. 1988

Intl Journal of Cancer

View full text Add to dashboard Cite

A syngeneic monoclonal antibody (MAb) (IC5F5) was successfully used in the immunotherapy of Rauscher-virus-induced myeloid leukemic RMB-I cells. It is directed to a virus-encoded, but aberrantly processed protein, which is expressed on the cell membrane. When applied in vivo, it binds only to RMB-I tumor cells. BALB/c mice were inoculated i.p. or i.v. with 10(7) RMB-I cells and died within 2-3 weeks due to increasing tumor load. Mice inoculated i.p. were completely cured by daily injections of ascites containing IC5F5. Disseminated tumor cells in liver and hemopoietic organs were observed after i.v. inoculation. Daily treatment with MAbs resulted in survival beyond 90 days. No antigenic modulation was observed when tumor tissue was analyzed 2-10 days after treatment. Treatment was successful even when therapy was postponed until day 5 following inoculation of tumor cells. When the number of ascites injections was reduced, survival was identical to that observed among repeatedly treated mice. Ten- and 100-fold dilution of ascites fluid diminished the number of survivors, but still resulted in a median survival time of 38 and 20 days, respectively, as compared to 14 days for untreated mice.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of syngeneic monoclonal antibodies in the therapy of disseminated myeloid leukemic cells

Berends

Mulder

Houwelingen

et al. 1988

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…The use of monoclonal antibodies has not been restricted to the analysis of cellular function. Clinical trials are underway to explore the effects of monoclonal antibodies as therapeutic tools for the treatment of malignant and immunoregulatory diseases (11)(12)(13)(14)(15)34). We have found that circulating Leu-1 antigen can be detected in the serum of patients after monoclonai antibody infusion (11).…”

Section: Discussionmentioning

confidence: 99%

Spontaneous release of the Leu-2 (T8) molecule from human T cells.

Fujimoto¹,

Levy²,

Levy³

1983

The Journal of Experimental Medicine

110

View full text Add to dashboard Cite

Sensitive enzyme-linked immunosorbent assays (ELISA) for the detection of human T cell antigens in soluble form have been developed. The assays use mouse monoclonal antibodies and specific anti-Leu sera prepared in rabbits by immunizing with Leu antigens absorbed to monoclonal antibody affinity columns. With these assays, Leu-1, -2, and -3 antigen signals from extracts of as few as 5 X 10(3) cells could be detected. When culture supernatants from various cell lines were tested, Leu-2 antigen, but not Leu-1 or Leu-3, was found to be present. Leu-2 antigen was present only in supernatants from T cell lines that expressed Leu-2 on their cell surface. Leu-2 antigen accumulated progressively in the supernatant of low density culture and its presence did not depend on cell proliferation or on fetal calf serum in the culture medium. The Leu-2 antigen in the supernatant was found to have only one Leu-2a determinant, whereas Leu-2 antigen from cell extracts had at least two determinants. The Leu-2 molecule was effectively purified from supernatant with an anti-Leu-2a affinity column. The purified Leu-2 antigen from supernatant of HPB-ALL cells was a single polypeptide chain of 27,000 mol wt, whereas Leu-2 antigen present on HPB-ALL cell surface was composed of two or more identical polypeptide chains of 33,000 mol wt linked by disulfide bonds. Normal human sera and sera from leukemia patients were also examined for the presence of the Leu-2 antigen. Normal human sera contained low levels of Leu-2 antigen but sera from Leu-2-positive leukemia patients had high levels. These results indicate that Leu-2 antigen is released from human T cells under physiological conditions.

show abstract

Fcγ-receptor–mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments

Taylor

Lindorfer

2015

Blood

134

118

View full text Add to dashboard Cite

A specialized form of trogocytosis occurs when Fcg receptors on acceptor cells take up and internalize donor cell-associated immune complexes composed of specific monoclonal antibodies (mAbs) bound to target antigens on donor cells. This trogocytosis reaction, an example of antigenic modulation, has been described in recent clinical correlative studies and in vitro investigations for several mAbs used in cancer immunotherapy, including rituximab and ofatumumab. We discuss the impact of Fcg-receptor-mediated trogocytosis on the efficacy of cancer immunotherapy and other mAb-based therapies. (Blood. 2015;125(5):762-766)

show abstract

Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia

Cited by 3 publications

References 0 publications

Use of syngeneic monoclonal antibodies in the therapy of disseminated myeloid leukemic cells

Use of syngeneic monoclonal antibodies in the therapy of disseminated myeloid leukemic cells

Spontaneous release of the Leu-2 (T8) molecule from human T cells.

Fcγ-receptor–mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments

Contact Info

Product

Resources

About